Onctura commences randomized Phase I/II study in non-small cell lung cancer First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good day and welcome to the Delcath Systems’ First Quarter 2025 ...

A young mum diagnosed with incurable cancer just weeks after giving birth to her son has completed the first cycle of a £200,000 treatment regime.

The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awarenes ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

"We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. "We look forward to the advancements to care we can make together for patients with GI diseases-our ...